| First Author | Seneviratne AK | Year | 2019 |
| Journal | Cell Stem Cell | Volume | 24 |
| Issue | 4 | Pages | 621-636.e16 |
| PubMed ID | 30930145 | Mgi Jnum | J:284785 |
| Mgi Id | MGI:6390088 | Doi | 10.1016/j.stem.2019.02.020 |
| Citation | Seneviratne AK, et al. (2019) The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids. Cell Stem Cell 24(4):621-636.e16 |
| abstractText | Tafazzin (TAZ) is a mitochondrial transacylase that remodels the mitochondrial cardiolipin into its mature form. Through a CRISPR screen, we identified TAZ as necessary for the growth and viability of acute myeloid leukemia (AML) cells. Genetic inhibition of TAZ reduced stemness and increased differentiation of AML cells both in vitro and in vivo. In contrast, knockdown of TAZ did not impair normal hematopoiesis under basal conditions. Mechanistically, inhibition of TAZ decreased levels of cardiolipin but also altered global levels of intracellular phospholipids, including phosphatidylserine, which controlled AML stemness and differentiation by modulating toll-like receptor (TLR) signaling. |
